Results
hypoglycemia
HYPOGLYCEMIA, REGRESSION
Participants included in the analysis (Baseline characteristics of the participants.Trial flowchart.Plasma glucose profiling for each of the four trial arms is shown in Plasma glucose profiles starting at 60 min before hypoglycemia treatment level was reached until 60 min after CHO consumption for the four trial arms.We report the comparison of 16 g vs. 32 g of CHO for the PG range 3.0–3.5 mmol/L in 32 participants. Delta-PG-15-min reached 0.1 (0.8) mmol/L vs. 0.6 (0.9) mmol/L, Outcomes of hypoglycemia treatment with 16 vs. 32 g oral CHO.Data presented as mean (SD) or n (%). *Primary endpoint. PG-T0 is plasma glucose at time 0, which is at the end of glucose tablets consumption. 2nd CHO treatment given at 15 min if PG still < 3 mmol/L and at 45 min if PG < 4 mmol/L. Rate of change of PG, insulin, and glucagon are calculated from hypoglycemia induction until first CHO consumption.Statistically significant p values were put in bold.We compare the consumption of 16 g vs. 32 g CHO intake for PG range < 3 mmol/L in 29 participants. Delta-PG-15-min reached 0.8 (0.9) mmol/L vs. 0.8 (1.0) mmol/L, At both hypoglycemia ranges, insulin boluses per kg of body weight used to induce hypoglycemia and plasma insulin and glucagon levels upon reaching hypoglycemia thresholds were comparable between arms (According to the best-fit regression model built for pooled data, significant predictors (